A Phase Ib Study to Determine the Maximum Tolerated Dose (MTD) of AZD1775 Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumours.
Phase of Trial: Phase I
Latest Information Update: 17 Aug 2017
At a glance
- Drugs AZD-1775 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors AstraZeneca
- 10 Aug 2017 Planned number of patients changed from 98 to 78.
- 20 Jun 2017 Planned End Date changed from 27 Feb 2018 to 9 Feb 2018.
- 20 Jun 2017 Planned primary completion date changed from 27 Feb 2018 to 9 Feb 2018.